Search clinical trials for: XPF-008

Total 3593 results

Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Scar Prevention

United States
Novo Nordisk A/S

Completed

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

Anemia

United States
Intra-Cellular Therapies, Inc.

Terminated

ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

Agitation in Dementia, Including Alzheimer's Disease

United States
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Czechia, Portugal, Hungary, Germany, Poland
Genentech, Inc.

Completed

A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

Hepatic Insufficiency

United States
Olympus Corporation

Terminated

A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema

Emphysema

Japan
Prof. Dr. Dieter Willbold
Medical University of Vienna; Alzheimer's Association; Helmholtz-Gemeinschaft... and other collaborators

Completed

MAD Phase I Study to Investigate Contraloid Acetate

Alzheimer Disease | Alzheimer Dementia

Germany
X4 Pharmaceuticals
Covance

Terminated

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Healthy

United States
Intra-Cellular Therapies, Inc.

Completed

Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia

Alzheimer's Disease

United States
Novo Nordisk A/S

Completed

Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

Healthy | Growth Hormone Disorder

Germany
Argos Therapeutics

Completed

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

HIV Infection

United States, Canada
Neurotec Pharma
Advancell - Advanced In Vitro Cell Technologies, S.A.

Completed

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis

Spain, Germany
East and North Hertfordshire NHS Trust
University of Hertfordshire

Unknown

Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS (VaLiDate-R)

Acute Coronary Syndrome

United Kingdom
Hutchison Medipharma Limited

Terminated

A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

Ulcerative Colitis

United States
Synthekine

Recruiting

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | NHL | CLL/SLL | Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
University of Alabama at Birmingham
Susan G. Komen Breast Cancer Foundation; Daiichi Sankyo UK Ltd.; Triple Negative...

Completed

Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Stage IV Breast Cancer

United States
Forest Laboratories

Completed

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR

MItochondrial Myopathies

United States, Denmark
Immune-Onc Therapeutics

Completed

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Advanced Solid Tumor

China
Immune-Onc Therapeutics
Regeneron Pharmaceuticals

Active, not recruiting

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
Fab'entech

Recruiting

Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome

COVID-19

Greece
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Recruiting

Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers

Healthy Volunteers

China
Inmagene LLC

Active, not recruiting

Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants

Healthy Volunteers

Australia
Reata, a wholly owned subsidiary of Biogen

Completed

A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers

Healthy

United States
Wave Life Sciences Ltd.

Terminated

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9)

ALS | FTD

Canada, Belgium, New Zealand, Netherlands, Australia, Sweden, United Kingdom, Ireland
Huahui Health

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

Hepatitis B

Australia
Equilibre Biopharmaceuticals B.V.

Completed

Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers

Safety Issues

United States
ValiRx Plc

Completed

Dose Finding Safety Study of VAL201 in Cancer Patients (VAL201-001)

Stage III Prostate Carcinoma | Stage IV Prostate Carcinoma
Arixa Pharmaceuticals

Unknown

A Single Ascending Dose Study of AV-006 in Healthy Subjects

Bacterial Infections

Australia
Cortendo AB

Completed

Levoketoconazole Food Effect Study in Healthy Subjects

Healthy Subjects

United States
Bonti, Inc.

Completed

Study to Evaluate EB-001 in Reducing Musculoskeletal Pain

Musculoskeletal Pain

United States
Synthetic Biologics Inc.

Completed

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

Clostridium Infections | Clostridium Difficile

United States, Bulgaria, Canada, Hungary, Poland, Romania, Serbia
Celularity Incorporated

Withdrawn

Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Diabetic Foot | Peripheral Arterial Disease

United States
University of California, Los Angeles
Massachusetts General Hospital; Washington University School of Medicine; University... and other collaborators

Completed

A Multicenter Study of NAP (AL-108) in Schizophrenia (AL-108)

Schizophrenia

United States
Cerenis Therapeutics, SA

Completed

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial (CHI SQUARE)

Acute Coronary Syndrome

Canada, United States, France, Netherlands
American Oriental Bioengineering, Inc.

Completed

Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency

Overactive Bladder

United States
Allon Therapeutics

Completed

Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

Mild Cognitive Impairment, So Stated

United States
Dow Pharmaceutical Sciences

Completed

The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Onychomycosis

United States, Canada
Sunnybrook Health Sciences Centre

Completed

Collagenase Total Occlusion-1 Trial

Chronic Total Occlusions

Canada
Corvus Pharmaceuticals, Inc.

Terminated

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

Covid-19

United States, Colombia, Spain, Canada, Peru, Brazil, Italy, Argentina, Chile, Germany, Mexico, Ukraine
X4 Pharmaceuticals

Not yet recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Neutropenia
Biogen

Not yet recruiting

A Study of Omaveloxolone in Children With Friedreich's Ataxia

Friedreich Ataxia

United States
National and Kapodistrian University of Athens
Harokopio University

Recruiting

High Protein Effect on Body Composition and Sarcopenia Markers in Older Patients With Type 2 Diabetes Mellitus

Type2 Diabetes Mellitus

Greece
MitoImmune Therapeutics

Recruiting

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients (MIT-001)

Head and Neck Squamous Cell Carcinoma | Oral Mucositis

Korea, Republic of, United States
Tianjin Medical University Second Hospital

Not yet recruiting

Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer

Lung Neoplasms | Oligometastasis
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER (DISCOVER)

Metastatic or Incurable Non-small Cell Lung Cancer | Relapsed, Refractory Melanoma

United States
Yung Shin Pharm. Ind. Co., Ltd.

Terminated

Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer (VMS)

Breast Cancer | Hot Flashes

Taiwan
PTC Therapeutics

Completed

A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia

BH4 Deficiency | Hyperphenylalaninemia

United States
Sumitomo Pharma America, Inc.

Completed

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

Healthy | ADME

United States

Search clinical trials for: XPF-008

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations